{"id":"NCT01621178","sponsor":"Eli Lilly and Company","briefTitle":"A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)","officialTitle":"A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-07","primaryCompletion":"2016-06","completion":"2016-12","firstPosted":"2012-06-18","resultsPosted":"2017-07-24","lastUpdate":"2019-09-19"},"enrollment":577,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes","Chronic Kidney Disease"],"interventions":[{"type":"DRUG","name":"Dulaglutide","otherNames":["LY2189265"]},{"type":"DRUG","name":"Insulin glargine","otherNames":[]},{"type":"DRUG","name":"Insulin lispro","otherNames":[]}],"arms":[{"label":"Insulin glargine","type":"ACTIVE_COMPARATOR"},{"label":"0.75 mg Dulaglutide","type":"EXPERIMENTAL"},{"label":"1.5 mg Dulaglutide","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine the glycemic efficacy and safety of dulaglutide compared to insulin glargine in the treatment of participants with type 2 diabetes and moderate or severe chronic kidney disease.","primaryOutcome":{"measure":"Change From Baseline in Hemoglobin A1c (HbA1c)","timeFrame":"Baseline, 26 Weeks","effectByArm":[{"arm":"Insulin Glargine","deltaMin":-1.13,"sd":0.12},{"arm":"Dulaglutide 0.75 mg","deltaMin":-1.12,"sd":0.12},{"arm":"Dulaglutide 1.5 mg","deltaMin":-1.19,"sd":0.13}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":12},"locations":{"siteCount":89,"countries":["United States","Brazil","Hungary","Mexico","Poland","Romania","South Africa","Spain","Ukraine"]},"refs":{"pmids":["39963952","29910024"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":56,"n":194},"commonTop":["Blood creatinine increased","Diarrhoea","Nausea","Glomerular filtration rate decreased","Vomiting"]}}